Executive Order orders the FDA to expedite psychedelic drug review

An executive order directs the FDA to speed up the review of psychedelic drugs. The focus is regulatory acceleration for psychedelic medicines, aiming to shorten timelines between development and potential access. This includes moving the drug review process faster than standard procedures. The change matters for how quickly psychedelic therapies can advance through FDA review, shaping timelines for clinical availability and future research momentum.